<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02043197</url>
  </required_header>
  <id_info>
    <org_study_id>P14-326</org_study_id>
    <nct_id>NCT02043197</nct_id>
  </id_info>
  <brief_title>Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder</brief_title>
  <acronym>FRIENDS</acronym>
  <official_title>Post-Marketing Observational Program of Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorders (FRIENDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Manipal Acunova Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, non-comparative, observational program to describe prevalence of
      depressive symptoms in a variety of neurological disorders and effects of Fevarin® on the
      severity of anxiety and depression, sleep state, and cognitive function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Different Neurological Disorders Associated With Depression Treated With Fluvoxamine (Fevarin®).</measure>
    <time_frame>Baseline</time_frame>
    <description>The primary neurologic diagnosis was coded according to International Classification of Diseases and Related Health Problems, revision 10 http://apps.who.int/classifications/icd10/browse/2010/en In the report all diseases were summarized by Classes. Percentage of patients reporting at least once a specified symptom during the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score</measure>
    <time_frame>From Baseline up to Day 30 and Day 90</time_frame>
    <description>HADS scale used under license agreement https://www.gl-assessment.co.uk/products/hospital-anxiety-and-depression-scale-hads/
The scale have two subscales:
HADS-Anxiety HADS-Depression
Each subscale has range 0-21 with following interpretation:
0-7 normal 8-10 mild 11-14 moderate 15-21 severe
In this place 'Change in the Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score' is presented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With Change of Depression Symptoms From Baseline to Day 30</measure>
    <time_frame>From Baseline up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score</measure>
    <time_frame>From Baseline up to Day 30 and Day 90</time_frame>
    <description>HADS scale used under license agreement https://www.gl-assessment.co.uk/products/hospital-anxiety-and-depression-scale-hads/
The scale have two subscales:
HADS-Anxiety HADS-Depression
Each subscale has range 0-21 with following interpretation:
0-7 normal 8-10 mild 11-14 moderate 15-21 severe
In this place 'Change in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score' is presented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Clinical Condition Measured by Clinical Global Impression Scale - Severity of Illness Subscale</measure>
    <time_frame>Baseline, Day 90</time_frame>
    <description>Clinical Global Impression Scale (CGI) was used. CGI is in the public domain. Severity of illness is the subscale of Clinical Global Impression (CGI). Severity of illness - reported in this place 0 = Not assessed, 1 = Normal, not at all ill, 2 = Borderline mentally ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Among the most extremely ill patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With Change in Clinical Global Impression Scale</measure>
    <time_frame>From Baseline up to Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and Depression Symptoms Score Measured by Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Up to 180 days</time_frame>
    <description>HADS scale used under license agreement https://www.gl-assessment.co.uk/products/hospital-anxiety-and-depression-scale-hads/
The scale have two subscales:
HADS-Anxiety HADS-Depression
Each subscale has range 0-21 with following interpretation:
0-7 normal 8-10 mild 11-14 moderate 15-21 severe
In this place Change in the Hospital Anxiety and Depression Scale (HADS) Both Subscale Scores are presented assessed at Day 180</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With Change of Anxiety Symptoms From Baseline to Day 30.</measure>
    <time_frame>From Baseline up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gender</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Race</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Family Status</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Education</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Employment</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Cognitive Functions Measured by Montreal Cognitive Assessment (MOCA)</measure>
    <time_frame>Baseline, Day 90, Up to 180 days</time_frame>
    <description>MoCA test used under license agreement www.mocatest.org
Scale range 0-30 Normal &gt;=26 Higher values represent a better outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>Baseline, Day 90, Up to 180 days</time_frame>
    <description>Insomnia Severity Index (ISI) used under license agreement cmorin@psy.ulaval.ca
Total score has the range from 0 to 28 points with the following categories:
0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe). Higher values represent a worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent of Patients With Quality of Sleep Change Assessed by Insomnia Severity Index (ISI) at Day 90</measure>
    <time_frame>From baseline up to Day 90</time_frame>
    <description>Percent of Patients With Quality of Sleep Change Assessed by Insomnia Severity Index (ISI) From Baseline to Day 90.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the Clinical Condition Measured by Clinical Global Impression Scale - Severity of Illness Subscale From Day 90 to 180 Days</measure>
    <time_frame>From Day 90 up to Up to 180 days</time_frame>
    <description>Clinical Global Impression Scale (CGI) was used. CGI is in the public domain. Severity of illness is the subscale of Clinical Global Impression (CGI). Severity of illness - reported in this place 0 = Not assessed, 1 = Normal, not at all ill, 2 = Borderline mentally ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Among the most extremely ill patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent of Patients With Change in Clinical Global Impression Scale - Global Improvement Subscale Assessed at Day 180</measure>
    <time_frame>From Day 90 up to 180 days</time_frame>
    <description>Global improvement - qualitative scale 0 = Not assessed, 1 = Very much improved , 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Outpatients with neurological disorders and depression.</arm_group_label>
    <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinics
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients with neurological disorders and mild or moderate symptoms of depression
             with Hospital Anxiety Depression Scale (HADS) depression scale score of 8 and higher.
             Fevarin® prescribed not earlier than 7 days before Visit 1.

        Exclusion Criteria:

          -  Labeled contraindications to Fevarin®, psychotic symptoms and/or suicidal ideation,
             schizophrenia, bipolar disorder, schizoaffective disorder, severe dementia, alcohol or
             drug abuse, acute neurological disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tatiana Vladimirova, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Facility ID ORG-000890</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454080</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facilility ID ORG-000872</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620141</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000881</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660037</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000893</name>
      <address>
        <city>Moscow</city>
        <zip>117342</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000882</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000876</name>
      <address>
        <city>Moscow</city>
        <zip>127644</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000877</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000889</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000880</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000879</name>
      <address>
        <city>Penza</city>
        <zip>440034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000891</name>
      <address>
        <city>Perm</city>
        <zip>614000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000840</name>
      <address>
        <city>Perm</city>
        <zip>614010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000803</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000898</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001028</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001027</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000894</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000897</name>
      <address>
        <city>Samara</city>
        <zip>443110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000839</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000873</name>
      <address>
        <city>Spassk-Dal'niy</city>
        <zip>692237</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000896</name>
      <address>
        <city>St. Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000892</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000965</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000878</name>
      <address>
        <city>Tver</city>
        <zip>170036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001026</name>
      <address>
        <city>Vladivostok</city>
        <zip>690024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000874</name>
      <address>
        <city>Volgograd</city>
        <zip>400007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000888</name>
      <address>
        <city>Volgograd</city>
        <zip>400009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000895</name>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000875</name>
      <address>
        <city>Yessentuki</city>
        <zip>357601</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>December 23, 2013</study_first_submitted>
  <study_first_submitted_qc>January 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <results_first_submitted>March 3, 2017</results_first_submitted>
  <results_first_submitted_qc>June 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2018</results_first_posted>
  <last_update_submitted>June 6, 2018</last_update_submitted>
  <last_update_submitted_qc>June 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression,</keyword>
  <keyword>depressive symptoms,</keyword>
  <keyword>major depressive disorder,</keyword>
  <keyword>Fevarine,</keyword>
  <keyword>fluvoxamine,</keyword>
  <keyword>cognitive function,</keyword>
  <keyword>neurological disorders,</keyword>
  <keyword>sleep state</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Outpatients With Neurological Disorders and Depression.</title>
          <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="292"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>299 patients were in the Intent-to-treat population 296 patients were in the Per Protocol population At each mesurement an actual number of assessed patients is presented</population>
      <group_list>
        <group group_id="B1">
          <title>Outpatients With Neurological Disorders and Depression.</title>
          <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="299"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="245"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.51" lower_limit="21" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Different Neurological Disorders Associated With Depression Treated With Fluvoxamine (Fevarin®).</title>
        <description>The primary neurologic diagnosis was coded according to International Classification of Diseases and Related Health Problems, revision 10 http://apps.who.int/classifications/icd10/browse/2010/en In the report all diseases were summarized by Classes. Percentage of patients reporting at least once a specified symptom during the treatment period.</description>
        <time_frame>Baseline</time_frame>
        <population>The actual number of assessed patients was provided to each measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Different Neurological Disorders Associated With Depression Treated With Fluvoxamine (Fevarin®).</title>
          <description>The primary neurologic diagnosis was coded according to International Classification of Diseases and Related Health Problems, revision 10 http://apps.who.int/classifications/icd10/browse/2010/en In the report all diseases were summarized by Classes. Percentage of patients reporting at least once a specified symptom during the treatment period.</description>
          <population>The actual number of assessed patients was provided to each measure.</population>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>International Classification of Diseases G00-G99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" lower_limit="43.4" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>International Classification of Diseases I00-I99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="26.5" upper_limit="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>International Classification of Diseases M00-M99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" lower_limit="15.7" upper_limit="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>International Classification of Diseases T00-T99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.2" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score</title>
        <description>HADS scale used under license agreement https://www.gl-assessment.co.uk/products/hospital-anxiety-and-depression-scale-hads/
The scale have two subscales:
HADS-Anxiety HADS-Depression
Each subscale has range 0-21 with following interpretation:
0-7 normal 8-10 mild 11-14 moderate 15-21 severe
In this place 'Change in the Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score' is presented</description>
        <time_frame>From Baseline up to Day 30 and Day 90</time_frame>
        <population>The actual number of assessed patients was provided to each measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score</title>
          <description>HADS scale used under license agreement https://www.gl-assessment.co.uk/products/hospital-anxiety-and-depression-scale-hads/
The scale have two subscales:
HADS-Anxiety HADS-Depression
Each subscale has range 0-21 with following interpretation:
0-7 normal 8-10 mild 11-14 moderate 15-21 severe
In this place 'Change in the Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score' is presented</description>
          <population>The actual number of assessed patients was provided to each measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6" spread="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With Change of Depression Symptoms From Baseline to Day 30</title>
        <time_frame>From Baseline up to Day 30</time_frame>
        <population>The actual number of assessed patients was provided to each measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With Change of Depression Symptoms From Baseline to Day 30</title>
          <population>The actual number of assessed patients was provided to each measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score</title>
        <description>HADS scale used under license agreement https://www.gl-assessment.co.uk/products/hospital-anxiety-and-depression-scale-hads/
The scale have two subscales:
HADS-Anxiety HADS-Depression
Each subscale has range 0-21 with following interpretation:
0-7 normal 8-10 mild 11-14 moderate 15-21 severe
In this place 'Change in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score' is presented</description>
        <time_frame>From Baseline up to Day 30 and Day 90</time_frame>
        <population>The actual number of assessed patients was provided to each measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score</title>
          <description>HADS scale used under license agreement https://www.gl-assessment.co.uk/products/hospital-anxiety-and-depression-scale-hads/
The scale have two subscales:
HADS-Anxiety HADS-Depression
Each subscale has range 0-21 with following interpretation:
0-7 normal 8-10 mild 11-14 moderate 15-21 severe
In this place 'Change in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score' is presented</description>
          <population>The actual number of assessed patients was provided to each measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Clinical Condition Measured by Clinical Global Impression Scale - Severity of Illness Subscale</title>
        <description>Clinical Global Impression Scale (CGI) was used. CGI is in the public domain. Severity of illness is the subscale of Clinical Global Impression (CGI). Severity of illness - reported in this place 0 = Not assessed, 1 = Normal, not at all ill, 2 = Borderline mentally ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Among the most extremely ill patients</description>
        <time_frame>Baseline, Day 90</time_frame>
        <population>The actual number of assessed patients was provided to each measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Clinical Condition Measured by Clinical Global Impression Scale - Severity of Illness Subscale</title>
          <description>Clinical Global Impression Scale (CGI) was used. CGI is in the public domain. Severity of illness is the subscale of Clinical Global Impression (CGI). Severity of illness - reported in this place 0 = Not assessed, 1 = Normal, not at all ill, 2 = Borderline mentally ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Among the most extremely ill patients</description>
          <population>The actual number of assessed patients was provided to each measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With Change in Clinical Global Impression Scale</title>
        <time_frame>From Baseline up to Day 90</time_frame>
        <population>The actual number of assessed patients was provided to each measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With Change in Clinical Global Impression Scale</title>
          <population>The actual number of assessed patients was provided to each measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimaly improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimaly worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anxiety and Depression Symptoms Score Measured by Hospital Anxiety and Depression Scale (HADS)</title>
        <description>HADS scale used under license agreement https://www.gl-assessment.co.uk/products/hospital-anxiety-and-depression-scale-hads/
The scale have two subscales:
HADS-Anxiety HADS-Depression
Each subscale has range 0-21 with following interpretation:
0-7 normal 8-10 mild 11-14 moderate 15-21 severe
In this place Change in the Hospital Anxiety and Depression Scale (HADS) Both Subscale Scores are presented assessed at Day 180</description>
        <time_frame>Up to 180 days</time_frame>
        <population>The actual number of assessed patients was provided to each measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Anxiety and Depression Symptoms Score Measured by Hospital Anxiety and Depression Scale (HADS)</title>
          <description>HADS scale used under license agreement https://www.gl-assessment.co.uk/products/hospital-anxiety-and-depression-scale-hads/
The scale have two subscales:
HADS-Anxiety HADS-Depression
Each subscale has range 0-21 with following interpretation:
0-7 normal 8-10 mild 11-14 moderate 15-21 severe
In this place Change in the Hospital Anxiety and Depression Scale (HADS) Both Subscale Scores are presented assessed at Day 180</description>
          <population>The actual number of assessed patients was provided to each measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HADS - D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HADS - A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With Change of Anxiety Symptoms From Baseline to Day 30.</title>
        <time_frame>From Baseline up to Day 30</time_frame>
        <population>The actual number of assessed patients was provided to each measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With Change of Anxiety Symptoms From Baseline to Day 30.</title>
          <population>The actual number of assessed patients was provided to each measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gender</title>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Gender</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Race</title>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Race</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Family Status</title>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Family Status</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Civil marriage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Divorced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Married</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Single</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Widow(er)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Education</title>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Education</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Elementary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>University</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Employment</title>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Employment</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Employed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unemployed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cognitive Functions Measured by Montreal Cognitive Assessment (MOCA)</title>
        <description>MoCA test used under license agreement www.mocatest.org
Scale range 0-30 Normal &gt;=26 Higher values represent a better outcome</description>
        <time_frame>Baseline, Day 90, Up to 180 days</time_frame>
        <population>The actual number of assessed patients was provided to each measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Functions Measured by Montreal Cognitive Assessment (MOCA)</title>
          <description>MoCA test used under license agreement www.mocatest.org
Scale range 0-30 Normal &gt;=26 Higher values represent a better outcome</description>
          <population>The actual number of assessed patients was provided to each measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Insomnia Severity Index</title>
        <description>Insomnia Severity Index (ISI) used under license agreement cmorin@psy.ulaval.ca
Total score has the range from 0 to 28 points with the following categories:
0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe). Higher values represent a worse outcome</description>
        <time_frame>Baseline, Day 90, Up to 180 days</time_frame>
        <population>The actual number of assessed patients was provided to each measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Insomnia Severity Index</title>
          <description>Insomnia Severity Index (ISI) used under license agreement cmorin@psy.ulaval.ca
Total score has the range from 0 to 28 points with the following categories:
0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe). Higher values represent a worse outcome</description>
          <population>The actual number of assessed patients was provided to each measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent of Patients With Quality of Sleep Change Assessed by Insomnia Severity Index (ISI) at Day 90</title>
        <description>Percent of Patients With Quality of Sleep Change Assessed by Insomnia Severity Index (ISI) From Baseline to Day 90.</description>
        <time_frame>From baseline up to Day 90</time_frame>
        <population>The actual number of assessed patients was provided to each measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With Quality of Sleep Change Assessed by Insomnia Severity Index (ISI) at Day 90</title>
          <description>Percent of Patients With Quality of Sleep Change Assessed by Insomnia Severity Index (ISI) From Baseline to Day 90.</description>
          <population>The actual number of assessed patients was provided to each measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in the Clinical Condition Measured by Clinical Global Impression Scale - Severity of Illness Subscale From Day 90 to 180 Days</title>
        <description>Clinical Global Impression Scale (CGI) was used. CGI is in the public domain. Severity of illness is the subscale of Clinical Global Impression (CGI). Severity of illness - reported in this place 0 = Not assessed, 1 = Normal, not at all ill, 2 = Borderline mentally ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Among the most extremely ill patients</description>
        <time_frame>From Day 90 up to Up to 180 days</time_frame>
        <population>The actual number of assessed patients was provided to each measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Clinical Condition Measured by Clinical Global Impression Scale - Severity of Illness Subscale From Day 90 to 180 Days</title>
          <description>Clinical Global Impression Scale (CGI) was used. CGI is in the public domain. Severity of illness is the subscale of Clinical Global Impression (CGI). Severity of illness - reported in this place 0 = Not assessed, 1 = Normal, not at all ill, 2 = Borderline mentally ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Among the most extremely ill patients</description>
          <population>The actual number of assessed patients was provided to each measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent of Patients With Change in Clinical Global Impression Scale - Global Improvement Subscale Assessed at Day 180</title>
        <description>Global improvement - qualitative scale 0 = Not assessed, 1 = Very much improved , 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse</description>
        <time_frame>From Day 90 up to 180 days</time_frame>
        <population>The actual number of assessed patients was provided to each measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Outpatients With Neurological Disorders and Depression.</title>
            <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With Change in Clinical Global Impression Scale - Global Improvement Subscale Assessed at Day 180</title>
          <description>Global improvement - qualitative scale 0 = Not assessed, 1 = Very much improved , 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse</description>
          <population>The actual number of assessed patients was provided to each measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimaly improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimaly worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>299 patients were in the Intent-to-treat population</desc>
      <group_list>
        <group group_id="E1">
          <title>Outpatients With Neurological Disorders and Depression.</title>
          <description>Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Hyperkinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Postural tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Psychogenic tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tatiana V. Vladimirova</name_or_title>
      <organization>Abbott</organization>
      <phone>+74952584280</phone>
      <email>tatiana.vladimirova@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

